Aspirin for the Primary Prevention of Cardiovascular Events

A systematic review and meta-analysis comparing patients with and without diabetes

Andrew D. Calvin, MD, MPH
Niti R. Aggarwal, MD
Mohammad Hassan Murad, MD, MPH
Qian Shi, PhD
Mohamed B. Elamin, MBBS
Jeffrey B. Geske, MD
M. Merc Fernandez-Balsells, MD
Felipe N. Albuquerque, MD
Juliana F. Lampley, MD
Patricia J. Erwin, MLS
Steven A. Smith, MD
Victor M. Montori, MD, MSC

OBJECTIVE — The negative results of two randomized controlled trials (RCTs) have challenged current guideline recommendations for using aspirin for primary prevention of cardiovascular events among patients with diabetes. We therefore sought to determine if the effect of aspirin for primary prevention of cardiovascular events and mortality differs between patients with and without diabetes.

RESEARCH DESIGN AND METHODS — We conducted a systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and Scopus since their inceptions until November 2008 for RCTs of aspirin for primary prevention of cardiovascular events. Blinded pairs of reviewers evaluated studies and extracted data. Random-effects meta-analysis and Bayesian logistic regression were used to estimate the ratios of relative risks (RRs) of outcomes of interest among patients with and without diabetes. A 95% CI that crosses 1.00 indicates that the effect of aspirin does not differ between patients with and without diabetes.

RESULTS — Nine RCTs with moderate to high methodological quality contributed data to the analyses. The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1.12 (95% CI 0.92–1.35), 1.19 (0.82–1.17), and 0.70 (0.25–1.97), respectively.

CONCLUSIONS — Whereas estimates of benefit among patients with diabetes remain imprecise, our analysis suggests that the relative benefit of aspirin is similar in patients with and without diabetes.

Cardiovascular events including myocardial infarction and ischemic stroke are the leading causes of morbidity and mortality in patients with diabetes, and the population burden of cardiovascular disease attributed to diabetes appears to be increasing (1). Several guidelines, including those of the American Diabetes Association, recommend aspirin for the primary prevention of cardiovascular events in patients with diabetes (2,3). Given that trials of aspirin for primary prevention have enrolled too few patients with diabetes, guideline panels have applied indirect evidence from other high-risk groups to formulate this recommendation (4). In contrast, other guidelines such as those of the European Society of Cardiology and the American Diabetes Association for the Study of Diabetes (5) and the most recent U.S. Preventive Services Task Force (6) provide no specific recommendations regarding the use of aspirin in patients with diabetes.

The best available estimate of the effect of aspirin comes from the most recent study from the Antithrombotic Trialists’ Collaborative, an individual-level meta-analysis of randomized controlled trials (RCTs) that reported a 12% reduction in the rate ratio of serious vascular events in patients with diabetes randomized to aspirin prophylaxis, although this finding was not statistically significant (rate ratio 0.88, 95% CI 0.67–1.15) (7). However, this meta-analysis did not include data from the Early Treatment Diabetic Retinopathy Study (ETDRS) (8) nor two recent primary prevention RCTs, the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) (9) and the Prevention of Progression of Arterial Disease and Diabetes (PO-PADAD) (10) studies. Results from both JPAD and POPADAD, however, were imprecise and unable to exclude a reduction in the risk for their composite end points of up to 42 and 24%, respectively.

We, therefore, set out to conduct a systematic review of RCTs of aspirin for primary prevention in patients with diabetes to 1) estimate the efficacy of aspirin for the primary prevention of cardiovascular events among patients with diabetes and 2) estimate the extent to which the effect of aspirin differs in patients with and without diabetes.

RESEARCH DESIGN AND METHODS — The report of this protocol-driven systematic review adheres to the Quality of Reporting of Meta-analyses (QUOROM) standards for reporting systematic reviews of randomized clinical trials (11).

Eligibility criteria
Eligible studies were RCTs that enrolled patients with diabetes without a prior history of myocardial infarction or stroke...
and assessed the efficacy of aspirin at any dosage.

Study identification and retrieval
An expert reference librarian designed and conducted the electronic search strategy. Our systematic search included MEDLINE, EMBASE, Cochrane Library, Web of Science, and Scopus, since their inceptions until November 2008. We used database-specific controlled language and terms that describe the key concepts: aspirin, diabetes, cardiovascular events, prevention, and randomized trials. We also reviewed the reference sections of identified reviews, published guidelines, and published manuscripts known to the authors. Study inclusion was not limited by publication status or language.

Pairs of reviewers, working independently and in duplicate, identified potentially eligible records for full-text retrieval from the titles and abstracts. Records in which the reviewers disagreed were also retrieved in full text. The reviewers assessed the retrieved full-text articles for eligibility. An independent reviewer resolved disagreements.

Outcomes
The outcomes of interest were ischemic stroke, myocardial infarction, and all-cause mortality.

Data abstraction
Two reviewers extracted the following data from each eligible article: description of study participants, study characteristics, and outcome data.

Quality assessment
Independent reviewers working in duplicate determined the extent to which trials reported concealment of allocation; blinding of patients, providers, and outcome assessors; and the extent of loss to follow-up.

Author contact
We contacted the corresponding and/or first author of each eligible article identified in the screening process by e-mail to confirm data extraction and quality assessment and to request missing information.

Prevention of cardiovascular events with aspirin
We used the \( \kappa \) statistic to quantify chance-adjusted agreement between reviewers for article selection. Random-effects meta-analyses estimated the pooled treatment effects (relative risks [RRs] and their 95% CIs) of aspirin in preventing cardiovascular events and all-cause death in patients with diabetes and without diabetes. The I\(^2\) statistic estimated the percentage of inconsistency across studies that was due to heterogeneity rather than chance or random error (12).

Given that subjects included in the Antiphospholipid Antibody–Acetylsalicylic Acid (APLASA) study were receiving aspirin for antiphospholipid antibody syndrome and had a short duration of follow-up and that a small number of subjects in ETDRS had suffered a prior stroke or myocardial infarction, we conducted sensitivity analysis to determine whether the exclusion of these studies affected the conclusions of this review.

Interaction between the effect of aspirin and diabetes status
We implemented three methods to determine whether a difference exists in aspirin effect in patients with and without diabetes. First, we estimated the ratio of RRs and its 95% CI using the method of Altman and Bland (13). This estimate compares the pooled RRs across subgroups of patients with diabetes and without across trials. Pooled estimates that exclude a ratio of 1 provide evidence of an aspirin-diabetes interaction. Second, we estimated the ratio of RRs comparing the aspirin effect in patients with and without diabetes within trials and then pooled these ratios. Again, pooled estimates that exclude a ratio of RRs of 1 indicate a statistically significant difference in the treatment effect of aspirin in patients with and without diabetes. We used Comprehensive Meta-Analysis version 2 software (Biostat, Englewood, NJ) and StatsDirect 2.5.4 (StatsDirect, Cheshire, U.K.) to conduct these analyses. Finally, we conducted a Bayesian random-effects logistic regression with aspirin use and diabetes status as the main effect factors, and an interaction term of these two was also applied to the included trials. A 95% credible interval of the regression coefficient of the interaction term that excludes 0 indicates that the effect of aspirin is different in patients with and without diabetes. This analysis was carried out using WinBUGS 1.4 (Medical Research Council and Imperial College of Science, Technology and Medicine, U.K.) with noninformative prior distributions and three parallel Markov Chain Monte Carlo chains with overdispersed initials. The Brooks-Gelman-Rubin (14) convergence diagnostic was applied to examine the convergence of the Markov Chain Monte Carlo samplers. Statistical inferences were then drawn based on the resulting posterior distributions of parameters of interest. For RCTs with zero events in one study arm, we used a continuity correction factor of 0.5 and conducted sensitivity analysis using the treatment arm method to test whether the choice of statistical methods affected study conclusions (15).

RESULTS

Search results
Figure 1 describes the process of study selection that yielded eight eligible RCTs.
Aspirin for primary prevention in diabetes

Table 1—Description of included trials

| Patient population | Inclusion age (years) | Participants (% female) | Participants with diabetes (%) | Aspirin treatment | Control | Average study duration (years) | Diabetes subgroup outcomes reported |
|--------------------|-----------------------|-------------------------|-------------------------------|-------------------|---------|-----------------------------|----------------------------------|
| APLASA (18)        | ≥18                   | 98 (90)                 | 6 (6)                         | 81 mg daily       | Placebo | 2.3                         | Mortality, MI, stroke            |
| Hypertension Optimal Treatment (19,27) | 50–80                 | 18,790 (47)             | 1,501 (8)                     | 75 mg daily       | Placebo | 3.8                         | Mortality, MI                    |
| ETDRS (8)          | 18–70                 | 3,711 (44)              | 3,711 (100)                   | 650 mg daily      | Placebo | 5.0                         | Mortality, MI                    |
| JPAD (9)           | 30–85                 | 2,539 (45)              | 2,539 (100)                   | 81 or 100 mg daily | Open label | 4.4                         | Mortality, MI, stroke            |
| Physicians’ Health Study (28) | ≥40                   | 22,071 (0)              | 533 (2)                       | 325 mg every other day | Placebo | 5.0                         | MI                              |
| POPADAD (24)       | ≥40                   | 1,276 (56)              | 1,276 (100)                   | 100 mg daily      | Placebo | 6.7                         | Mortality, MI                    |
| Primary Prevention Project (29) | ≥50                   | 1,031 (32)              | 1,031 (100)                   | 100 mg daily*     | Open label | 3.6                         | MI, stroke                       |
| Women’s Health Study (17) | ≥50                   | 39,876 (100)            | 1,037 (3)                     | 100 mg every other day† | Placebo | 10.1                        | MI, stroke                       |

CVD, cardiovascular disease; MI, myocardial infarction; PAD, peripheral arterial disease. *Also randomized to vitamin E. †Also randomized to β-carotene.

Table 2—Risk of bias in included trials

| Blinding caregivers | Blinding: patients | Blinding: outcome assessors | Blinding: data collectors | Allocation concealment | Lost to follow-up | Funding source | Trial stopped early |
|---------------------|--------------------|-----------------------------|---------------------------|------------------------|-------------------|----------------|---------------------|
| APLASA              | Yes                | Yes                         | Yes                       | Yes                    | 5%                | FP             | No                  |
| ETDRS               | Yes                | Yes                         | Yes                       | Yes                    | >10%              | NFP            | No                  |
| Hypertension Optimal Treatment | Yes | Yes | Yes | Yes | Yes | Yes | No |
| JPAD                | No                 | No                          | Yes                       | Yes                    | 8%                | NFP            | No                  |
| Physicians’ Health Study | Yes | Yes | Yes | Yes | Yes | Yes | No |
| POPADAD             | Yes                | Yes                         | Yes                       | Yes                    | <1%               | FP             | No                  |
| Primary Prevention Project | No | No | NR | No | Yes | NR/NC | Yes |
| Women’s Health Study | Yes | Yes | Yes | Yes | No | NR/NC | FP |

FP, includes for-profit sources; NFP, does not include for-profit sources; NR/NC, profit status not reported or not clear.
Interaction between the effect of aspirin and diabetes status

Table 3 describes the results of between-study subgroup analysis, within-study subgroup analyses, and Bayesian random-effects regression analyses. All three methods yielded nonsignificant ratios of RR of aspirin in patients with and without diabetes across all outcomes examined. The choice of continuity correction method for RCTs with zero events in one arm did not substantially affect inferences.
Aspirin for primary prevention in diabetes

Table 3—Aspirin-diabetes subgroup interaction analyses

|                  | RR* with diabetes | RR* without diabetes | Ratio of RRs pooled across trials | Ratio of RRs pooled within trials | Ratio of RRs Bayesian analyses |
|------------------|-------------------|----------------------|-----------------------------------|-----------------------------------|--------------------------------|
| Mortality        | 0.97 (0.87–1.08)  | 0.87 (0.75–1.02)     | 1.12 (0.92–1.35)                  | 1.00 (0.53–1.88)                  | 1.16 (0.09–13.79)              |
| Myocardial infarction | 0.86 (0.67–1.11) | 0.72 (0.55–0.95)     | 0.36                              | 1.02 (0.71–1.47)                  | 1.06 (0.16–6.71)               |
| Ischemic stroke  | 0.62 (0.31–1.24)  | 0.89 (0.41–1.94)     | 0.50                              | 0.93 (0.37–2.34)                  | 0.47 (<0.01–20.52)             |

*Sensitvity analysis

Our conclusions were not significantly altered by the exclusion of the APLASA ($P_{interaction}$ 0.28, 0.36, and 0.63 for mortality, myocardial infarction, and ischemic stroke, respectively) or ETDRS trials ($P_{interaction}$ 0.18, 0.62, and 0.48 for mortality, myocardial infarction, and ischemic stroke, respectively).

**CONCLUSIONS** — Consistent with prior studies (7,9,10), we found no significant benefit of aspirin therapy for the primary prevention of cardiovascular events among patients with diabetes. Even for the outcome of myocardial infarction, in which the overall risk reduction was statistically significant, our estimated risk reduction among patients with diabetes remained nonsignificant. However, our estimates were imprecise and unable to exclude a treatment benefit of 13, 33, and 69% for the outcomes of mortality, myocardial infarction, and ischemic stroke, respectively. Using a between-studies approach, a within-studies approach, and a Bayesian analysis, we found evidence that the effect of aspirin among patients with diabetes was not significantly different from patients without diabetes. Thus, the data we present here provide imprecise evidence of benefit from using aspirin in patients with diabetes without a history of cardiovascular events; this treatment effect does not differ significantly from that observed in patients without diabetes.

Limitations and strengths

The main limitation of our study relates to our use of published aggregate data and lack of statistical power. The possibility of publication bias cannot be adequately assessed and corrected given the small number of RCTs (20). Our comprehensive literature search minimized the risk of publication and reporting biases, although our author response rate was relatively low and resulted in less complete data. It is possible that other aspirin RCTs have examined diabetes subgroups but have not reported these results because of lack of a significant aspirin-diabetes interaction. If this were to be the case, their inclusion would likely strengthen our conclusions. The small number of included trials and the small number of events within these trials reduced the statistical power and therefore the precision of the estimates in our main analysis and in our tests for interaction between aspirin effect and diabetes status. Our analyses using multiple statistical methods to examine the diabetes-aspirin interaction and their consistent results strengthen our conclusions. While the use of composite end points would have increased our statistical power, we chose to pool individual end points because the composite end points in the included trials represent outcomes with large gradients in importance to patients and in potential magnitude of the effect of treatment across component end points (21). We did not examine the potential harm from aspirin therapy such as gastrointestinal bleeding, since these events in the small population of patients with diabetes included in RCTs are usually rare, leading to imprecise estimates. Hence, evidence about harm is better obtained from larger studies that include patients without diabetes.

Implications

Our inferences should be considered in the context of proposed criteria to evaluate the validity of a subgroup effect (22). Good evidence of a valid subgroup effect results from testing few a priori hypotheses based on strong biological rationale. The extent to which this is true for the diabetes subgroup analyses reported in the literature is unclear to us. Our analyses, however, do not support other criteria for a valid subgroup effect. We found that differences in aspirin treatment effect between patients with and without diabetes, both between and within RCTs, were inconsistent and of small magnitude. Thus, the current best evidence suggests that the efficacy of aspirin for the primary prevention of cardiovascular events in patients with diabetes is similar to that in patients without diabetes.

The decision to use aspirin for primary prevention in individual patients with diabetes remains a complex issue. Ultimately, the decision to use aspirin for an individual patient should consider the advantages and disadvantages of this preventive treatment given the patient’s context and preferences. We suggest first estimating the 10-year risk of coronary heart disease (23,24). Multiplying this estimate by 0.88 (12% relative risk reduction with the use of aspirin based on data from the Anti-thrombotic Trialists’ Collaborative [7]) would provide the revised 10-year risk estimate for a patient using aspirin. This should be presented alongside the risk of major gastrointestinal and extracranial bleeds with and without aspirin (7,25). A patient decision aid could present these data to help patients and clinicians consider the relative merits and downsides of aspirin use, as was done recently for use of statin therapy in patients with diabetes (26).

Summary

While there are insufficient data among patients with diabetes to conclusively...
show a benefit of aspirin therapy for the primary prevention of cardiovascular events, our data suggest, but do not confirm, that the relative benefit of aspirin is similar in patients with and without diabetes. Additional evidence from RCTs and individual-patient-data meta-analyses may help to further clarify this issue.

Acknowledgments—A.D.C. was supported by the Mayo Clinic Clinician–Investigator Training Program. M.M.F.-B. received grant support from the Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo (BA08/90035), Government of Spain.

No potential conflicts of interest relevant to this article were reported.

We wish to sincerely thank all of the study authors who promptly and graciously responded to our requests for information.

References

1. Fox CS, Coady S, Sorlie PD, D’Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1534–1550

2. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007;30:S9–S41

3. Colwell JA, for the American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004;27:S52–S73

4. Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA 2008;300:2180–2181

5. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Costenino F, Jonsson B, Laakso M, Malmberg K, Priori S, Östergren J, Tuomilehto J, Thrainsdottir I, Other C, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc J-J, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterpdy Ar, Tamargo M, Zamorano JL, Document R, Deckers JW, Bernard M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlike H, Juanatey JRG, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88–136

6. Wollf T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405–410

7. Antithrombotic Trials’ Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Petro R, Buring J, Hennelens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860

8. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1929–1930

9. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinmouch H, Sugiyama S, Saito Y. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Low-dose aspirin for primary prevention of atherothrombotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–2141

10. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jorg R, Kelly C, Connacher A, Peden N, Jameson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Pietri J, Gotzsche P, Nettle B, MacFarlane P, Walter R. Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group; and Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840

11. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896–1900

12. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560

13. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326:219

14. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434–455

15. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–1375 [erratum in Stat Med 2006;25:2700]

16. Lavel Langhennig R, Ruttman B, Schiele I, Schäfer W, Aisch W. 5-year controlled ther-apy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid. Z Gesamte Inn Med 1982;37:661–665 [in German]

17. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304

18. Erlkan D, Harrison M, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yacizi Y, Lockshin M. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382–2391

19. Hansson L, Zanchetti A, Carruthers SG, Dahlb E, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762

20. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597–600

21. Ferreira-Gonzalez I, Permanyer-Miralda G, Domingo-Salvany A, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Up- adhye S, Jaeschke R, Schünemann HJ, Pachecho-Huergo V, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786

22. Guyatt G, Wyer P, Ioannidis J. When to believe a subgroup analysis. In: Users’ Guides to the Medical Literature. 2nd ed. Guyatt G, Rennie D, Meade MO, Cook DJ, Eds. New York, McGraw-Hill, 2008, p. 571–593

23. Stevens RJ, Kothari V, Adel A, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671–679

24. UKPDS Risk Engine [version 2.01 online], 2009. Available from http://www.dtu.ox.ac.uk/index.php?maindoc=2=riskeengine. Accessed 7 August 2009

25. Aspirin for the Prevention of Cardiovascular Disease, Topic Page. March 2009. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. Available from http://www.ahrq.gov/clinic/uspspt/uspsasmi.htm

26. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christian-son TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice ran-
domized trial. Arch Intern Med 2007; 
167:1076–1082

27. Zanchetti A. Aspirin and Antiplatelet Drugs 
in the Prevention of Cardiovascular Compli-
cations of Diabetes. New York, Springer 
Science, 2007

28. Steering Committee of the Physicians’ 
Health Study Research Group. Final re-
port on the aspirin component of the on-
going Physicians’ Health Study. N Engl 
J Med 1989;321:129–135

29. Sacco M, Pellegrini F, Roncaglioni MC, Avan-
zini F, Tognoni G, Nicolucci A, Group PPP 
Collaborative Group. Primary prevention of 
cardiovascular events with low-dose aspirin 
and vitamin E in type 2 diabetic patients: re-
sults of the Primary Prevention Project (PPP) 
trial. Diabetes Care 2003;26:3264–3272